The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Open accessAbstract
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa cases become castration resistant (CRPCa). Several mechanisms can guide treatment resistance to anti-AR molecules. In this regard, AR-dependent and -independent resistance mechanisms can be distinguished within the AR pathway. In this article, we investigate the multitude of AR signaling aspects, encompassing the biological structure of AR, current AR-targeted therapies, mechanisms driving resistance to AR, and AR crosstalk with other pathways, in an attempt to provide a comprehensive review for the PCa research community. We also summarize the new anti-AR drugs approved in non-metastatic castration-resistant PCa, in the castration-sensitive setting, and combination therapies with other drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633 · cited 1×
“It should be noted that, especially in patients previously treated with docetaxel, side effects, including seizures, were mostly associated with the enzalutamide arm [87].”
BackgroundApalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 738
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 561
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
The androgen receptor gene mutations database: 2012 update
Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M., & Trifiro, M. (2012) · Human Mutation · doi:10.1002/humu.22046 · Cited by 512
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003892 · Cited by 428
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380
Tan, J.-A. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.450 · Cited by 375
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Malignant transformation in a nontumorigenic human prostatic epithelial cell line.
Hayward, S. W., Wang, Y. Z., Cao, M., Hom, Y. K., Zhang, B., Grossfeld, G. D., Sudilovsky, D., & Cunha, G. R. (2001) · PubMed · Cited by 345
Molecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336
(1994) · PubMed Central · Cited by 328
Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317
Del Re, M., Biasco, E., Crucitta, S., Derosa, L., Rofi, E., Orlandini, C., Miccoli, M., Galli, L., Falcone, A., Jenster, G. W., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.012 · Cited by 284
Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx155 · Cited by 269
The Androgen Receptor in Health and Disease
Matsumoto, T., Sakari, M., Okada, M., Yokoyama, A., Takahashi, S., Kouzmenko, A., & Kato, S. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183656 · Cited by 266
Scher, H. I., Graf, R. P., Schreiber, N. A., Jayaram, A., Winquist, E., McLaughlin, B., Lu, D., Fleisher, M., Orr, S., Lowes, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1621 · Cited by 241
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
Chan, S. C., Li, Y., & Dehm, S. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352930 · Cited by 218
Steinkamp, M. P., O'Mahony, O. A., Brogley, M., Rehman, H., LaPensee, E. W., Dhanasekaran, S., Hofer, M. D., Kuefer, R., Chinnaiyan, A., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3605 · Cited by 210
Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L. (2001) · PubMed · Cited by 208
Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens
Wilding, G., Chen, M., & Gelmann, E. P. (1989) · The Prostate · doi:10.1002/pros.2990140204 · Cited by 205
Chen, E. J., Sowalsky, A. G., Gao, S., Cai, C., Voznesensky, O., Schaefer, R., Loda, M., True, L. D., Ye, H., Troncoso, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1220 · Cited by 182
Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., & Tilley, W. D. (2001) · PubMed · Cited by 181
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
Nakazawa, M., Lu, C., Chen, Y., Paller, C. J., Carducci, M. A., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv282 · Cited by 178
Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Leung, J. K., & Sadar, M. D. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00002 · Cited by 177
Decoding the androgen receptor splice variants.
Lu, C., & Luo, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.08 · Cited by 157
Palmberg, C., Koivisto, P. A., Kakkola, L., Tammela, T. L. J., Kallioniemi, O., & Visakorpi, T. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66935-2 · Cited by 151
Δ 5 -Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells
Miyamoto, H., Yeh, S., Lardy, H. A., Messing, E. M., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11083 · Cited by 147
Androgen receptor and its splice variants in prostate cancer
Haile, S., & Sadar, M. D. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0766-7 · Cited by 136
Dalal, K., Roshan‐Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., Leblanc, E., Dehm, S. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553818 · Cited by 135
Salvi, S., Casadio, V., Conteduca, V., Burgio, S. L., Menna, C., Bianchi, E., Rossi, L., Carretta, E., Masini, C., Amadori, D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.128 · Cited by 128
Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
Patel, G. K., Chugh, N., & Tripathi, M. (2019) · Cancers · doi:10.3390/cancers11101405 · Cited by 126
Ricciardelli, C., Choong, C. S., Buchanan, G., Vivekanandan, S., Neufing, P. J., Stahl, J., Marshall, V. R., Horsfall, D. J., & Tilley, W. D. (2004) · The Prostate · doi:10.1002/pros.20154 · Cited by 116
Stromal Androgen Receptor in Prostate Development and Cancer
Singh, M., Jha, R., Melamed, J., Shapiro, E., Hayward, S. W., & Lee, P. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.022 · Cited by 95
Olapade-Olaopa, E. O., MacKay, E. H., Taub, N. A., SANDHU, D. P. S., Terry, T. R., & Habib, F. K. (1999) · PubMed · Cited by 94
AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
Liu, G., Sprenger, C. C. T., Sun, S., Epilepsia, K. S., Haugk, K. L., Zhang, X., Coleman, I. M., Nelson, P. S., & Plymate, S. R. (2013) · Neoplasia · doi:10.1593/neo.13784 · Cited by 83
Li, Y., Li, C. X., Ye, H., Chen, F., Melamed, J., Peng, Y., Liu, J., Wang, Z., Tsou, H. C., Wei, J., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00279.x · Cited by 79
Mononen, N., Syrjäkoski, K., Matikainen, M. P., Tammela, T. L. J., Schleutker, J., Kallioniemi, O., Trapman, J., & Koivisto, P. A. (2000) · PubMed · Cited by 78
Lotan, T. L., Tomlins, S. A., Bismar, T. A., van der Kwast, T., Grignon, D. J., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., & Bubendorf, L. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001450 · Cited by 75
Hayward, S. W., Haughney, P. C., Lopes, E. S., Danielpour, D., & Cunha, G. R. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990515)39:3<205::aid-pros9>3.0.co;2-m · Cited by 66
UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1
Nicolau‐Neto, P., Palumbo, A., Martino, M. D., Esposito, F., Simão, T. D. A., Fusco, A., Nasciutti, L. E., Costa, N. M. D., & Pinto, L. F. R. (2018) · Genes · doi:10.3390/genes9040188 · Cited by 66
Crnalic, S., Hörnberg, E., Wikström, P., Lerner, U. H., Tieva, Å., Svensson, O., Widmark, A., & Bergh, A. R. J. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0059 · Cited by 61
Tanner, M. J., Welliver, C., Chen, M., Shtutman, M. S., Godoy, A., Smith, G. J., Mian, B. M., & Buttyan, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016027 · Cited by 60
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Alyamani, M., Emamekhoo, H., Park, S., Taylor, J., Almassi, N., Upadhyay, S., Tyler, A. J., Berk, M. P., Hu, B., Hwang, T. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98319 · Cited by 60
Zhu, Y., Sharp, A., Anderson, C. M., Silberstein, J. L., Taylor, M. N., Lu, C., Zhao, P., Marzo, A. M. D., Antonarakis, E. S., Wang, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.009 · Cited by 59
Okegawa, T., Ninomiya, N., Masuda, K., Nakamura, Y., Tambo, M., & Nutahara, K. (2018) · The Prostate · doi:10.1002/pros.23501 · Cited by 56
Androgen receptor plasticity and its implications for prostate cancer therapy
Snow, O., Lallous, N., Singh, K., Lack, N. A., Rennie, P. S., & Cherkasov, A. R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.001 · Cited by 56
A Whole Blood Assay for AR-V7 and ARv567esin Patients with Prostate Cancer
Liu, X., Ledet, E. M., Li, D., Dotiwala, A. K., Steinberger, A. E., Feibus, A. H., Li, J., Qi, Y., Silberstein, J. L., Lee, B., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.06.095 · Cited by 54
Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells
Sánchez, B. G., Bort, A., Vara‐Ciruelos, D., & Díaz‐Laviada, I. (2020) · Cells · doi:10.3390/cells9061441 · Cited by 45
Targeting rapid action of sex steroid receptors in breast and prostate cancers
Giovannelli, P., Donato, M. D., Giraldi, T., Migliaccio, A., Castoria, G., & Auricchio, F. (2011) · Frontiers in bioscience · doi:10.2741/3849 · Cited by 44
Luo, J. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178490 · Cited by 43
Tamburrino, L., Salvianti, F., Marchiani, S., Pinzani, P., Nesi, G., Serni, S., Forti, G., & Baldi, E. (2012) · Steroids · doi:10.1016/j.steroids.2012.01.008 · Cited by 41
McAllister, M. J., Underwood, M. A., Leung, H. Y., & Edwards, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.11.004 · Cited by 35
Steroid signaling activation and intracellular localization of sex steroid receptors
Giraldi, T., Giovannelli, P., Donato, M. D., Castoria, G., Migliaccio, A., & Auricchio, F. (2010) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-010-0103-1 · Cited by 27
Podolak, J., Eilers, K. M., Newby, T. A., Slottke, R., Tucker, E., Olson, S. B., Lue, H.-W., YOUNGREN, J. F., Aggarwal, R. R., Small, E. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16169 · Cited by 27
Targeting rapid action of sex-steroid receptors in breast and prostate cancers
Castoria, G. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e390 · Cited by 23
Tripathi, A., Supko, J. G., Gray, K. P., Melnick, Z. J., Regan, M. M., Taplin, M., Choudhury, A. D., Pomerantz, M. M., Joaquim Bellmunt, B., Yu, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2306 · Cited by 21
Targeting rapid action of sex-steroid receptors in breast and prostate cancers
Giovannelli, P. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/390 · Cited by 13
Moigne, R. L., Banuelos, C. A., Mawji, N. R., Tam, T. W., Wang, J., Jian, K., Andersen, R. J., Cesano, A., Sadar, M. D., Zhou, H.-J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.142 · Cited by 12
Jayaram, A., Wetterskog, D., & Attard, G. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0124 · Cited by 7
Author response: Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M., Evans, M. J., Hosfield, D. J., et al. (2013) · doi:10.7554/elife.00499.041 · Cited by 4
Cited by
Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 355
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Metadata
- Authors
- Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-12-10
- Volume
- 9
- Issue
- 12
- Pages
- 2653
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3112880576
- Cited by
- 258
- References
- 91
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.